Company Filing History:
Years Active: 2011-2016
Title: **Jong Pil Min: Innovator in Diabetes Treatment**
Introduction
Jong Pil Min is a notable inventor based in Yongin-si, South Korea, recognized for his contributions to the field of pharmaceutical innovations, particularly in the development of dipeptidyl peptidase-IV (DPP-IV) inhibitors. With a total of four patents to his name, Min has been at the forefront of advancing diabetes treatments through innovative methodologies.
Latest Patents
Among his latest patents, Jong Pil Min has developed two significant methods related to dipeptidyl peptidase-IV inhibitors. The first patent is titled "Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate." This invention offers an improved approach to preparing DPP-IV inhibitor intermediates by utilizing low-cost reagents, leading to reduced preparation costs and enhanced yield for mass production. The second patent, "Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate," similarly focuses on cost-effectiveness and improved production efficiency using low-cost reagents, making it adaptable for widespread manufacturing.
Career Highlights
Throughout his career, Jong Pil Min has made significant strides in pharmaceutical research, primarily focusing on innovative drug formulation and production processes. His work has the potential to lower costs significantly, thereby increasing accessibility to critical diabetes medications.
Collaborations
Min has collaborated with notable peers in the industry, including Heung Jae Kim and Woo Young Kwak. His associations with established companies such as Dong-a Pharmaceutical Co., Ltd and Dong-a Pharm. Co., Ltd underscore his role in the advancement of pharmaceutical technologies and innovations.
Conclusion
Jong Pil Min continues to be an influential figure in the field of pharmaceutical innovation. His contributions to the development of effective DPP-IV inhibitors not only showcase his inventive capabilities but also promise advancements in the treatment of diabetes, ultimately benefiting patients worldwide.